Patents Assigned to Academy of Military Medical Science, PLA
-
Publication number: 20230022109Abstract: Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.Type: ApplicationFiled: June 15, 2020Publication date: January 26, 2023Applicants: ACADEMY OF MILITARY MEDICAL SCIENCE, PLA, CANSINO BIOLOGICS INC.Inventors: Wei Chen, Shipo Wu, Lihua Hou, Zhe Zhang, Busen Wang, Qiang Guo, Jinlong Zhang, Xiaohong Song, Ling Fu, Jun Zhang, Yi Chen, Zhenghao Zhao, Tao Zhu, Jin Li, Chunlin Xin
-
Publication number: 20220315949Abstract: A single plasmid vector system for packaging recombinant human adenovirus type 4. The vector system contains an E3 region-deleted human adenovirus type 4 (HAdV-4 or Ad4) genome, a vector sequence for amplifying plasmids in bacteria, a pBR322 replication origin, a kanamycin resistance gene, and a replication control sequence; and an exogenous gene embedding site is located behind a packaging signal of the human adenovirus type 4 and in front of an E1 region. The present invention further provides a method for packaging the recombinant human adenovirus type 4 by the single plasmid vector system and an application in vaccine and drug preparation. The vector system can be used for rapidly and efficiently preparing a human adenovirus type 4 vector recombinant virus for stably expressing an exogenous gene, and has a good application prospect in the fields of preparation of a diagnostic kit, a vaccine, a gene therapy kit and/or a tumor therapy drug, etc.Type: ApplicationFiled: September 26, 2019Publication date: October 6, 2022Applicant: ACADEMY OF MILITARY MEDICAL SCIENCE, PLAInventors: Wei Chen, Busen Wang, Lihua Hou, Shipo Wu, Qiang Guo, Zhe Zhang, Zhenghao Zhao, Jinlong Zhang, Ling Fu, Xiaohong Song
-
Patent number: 11453704Abstract: The present invention relates to a nucleotide sequence as shown in SEQ ID NO: 1 for encoding a Marburg virus envelope glycoprotein, and to a human replication-deficient recombinant adenovirus capable of expressing the nucleotide sequence and a preparation method therefor, as well as an application thereof in the preparation of a vaccine against Marburg virus disease. The vaccine uses an E1 and E3 deleted replication-deficient human type-5 adenovirus as a vector, and HEK293 cells integrating an adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is a codon-optimized Marburg virus Angola strain envelope glycoprotein gene. After codon optimization of the envelope glycoprotein gene, significant expression of envelope glycoprotein can be detected in transfected cells.Type: GrantFiled: August 27, 2018Date of Patent: September 27, 2022Assignee: Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Yanbo Wen, Zhe Zhang, Busen Wang, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Patent number: 11369587Abstract: The present invention relates to a pharmaceutical composition of Tecovirimat for injection, comprising Tecovirimat as an active ingredient, cyclodextrin and an additive. The present invention also relates to a method for preparing the pharmaceutical composition. The composition improves the solubility of Tecovirimat in water by using cyclodextrin and meglumine in combination, as compared with the solubility of Tecovirimat in water by using cyclodextrin or meglumine alone.Type: GrantFiled: July 4, 2017Date of Patent: June 28, 2022Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA ChinaInventors: Wu Zhong, Meiyan Yang, Wei Gong, Yuli Wang, Chunsheng Gao, Xinbo Zhou, Song Li
-
Patent number: 11205502Abstract: Provided are a processing method and a processing apparatus for efficacy of a combined drug. The processing method includes: obtaining dose-effect curve band of expected additive effect of the combined drug; obtaining actual dose-effect relationship curve formed by actual effect value of the combined drug with a dose change of one target component drug in the combined drug; comparing a positional relationship between the actual dose-effect relationship curve and the dose-effect curve band; and outputting the efficacy of the combined drug as a synergistic effect when the actual dose-effect relationship curve is located above the dose-effect curve band, outputting the efficacy of the combined drug as an antagonistic effect when the actual dose-effect relationship curve is located below the dose-effect curve band, and outputting the efficacy of the combined drug as an additive effect when the actual dose-effect relationship curve is located within a range of the dose-effect curve band.Type: GrantFiled: August 31, 2016Date of Patent: December 21, 2021Assignee: Institute of radiation medicine, academy of military medical sciences, PLA.Inventors: Shoujun Yuan, Linna Li, Dexuan Yang
-
Publication number: 20200392188Abstract: The present invention relates to a nucleotide sequence as shown in SEQ ID NO: 1 for encoding a Marburg virus envelope glycoprotein, and to a human replication-deficient recombinant adenovirus capable of expressing the nucleotide sequence and a preparation method therefor, as well as an application thereof in the preparation of a vaccine against Marburg virus disease. The vaccine uses an E1 and E3 deleted replication-deficient human type-5 adenovirus as a vector, and HEK293 cells integrating an adenovirus E1 gene as a packaging cell line, and a protective antigen gene carried is a codon-optimized Marburg virus Angola strain envelope glycoprotein gene. After codon optimization of the envelope glycoprotein gene, significant expression of envelope glycoprotein can be detected in transfected cells.Type: ApplicationFiled: August 27, 2018Publication date: December 17, 2020Applicant: Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Yanbo Wen, Zhe Zhang, Busen Wang, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Patent number: 10705005Abstract: The present invention discloses a unit for validating an in situ decontamination effect, including a connecting end. A left end of the connecting end is in communication with any space that needs gas decontamination. A right end of the connecting end is connected to a closed isolation damper. A right end of the closed isolation damper is connected to a hollow decontamination validation chamber. A sealing cover is sleeved over an outer wall of the decontamination validation chamber. A mesh cup is placed inside the decontamination validation chamber, and the mesh cup is used for placing a bioindicator. In addition, the present invention further discloses a device for filtering biologically contaminated air, including a unit for validating an in situ decontamination effect and a hollow box installed with a high efficiency particulate air (HEPA) filter. The unit for validating an in situ decontamination effect is in communication with the hollow box.Type: GrantFiled: March 9, 2018Date of Patent: July 7, 2020Assignee: Institute of Medical Equipment, Academy of Military Medical Sciences, PLAInventors: Jiancheng Qi, Zongxing Zhang, Ying Yi, Jinhui Wu
-
Patent number: 10172932Abstract: Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.Type: GrantFiled: October 24, 2016Date of Patent: January 8, 2019Assignee: Institute of Biotechnology, Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Publication number: 20180264100Abstract: Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.Type: ApplicationFiled: October 24, 2016Publication date: September 20, 2018Applicant: Institute of Biotechnology, Academy of Military Medical Science, PLAInventors: Wei Chen, Shipo Wu, Lihua Hou, Xiaohong Song, Jinlong Zhang, Ling Fu
-
Patent number: 9642839Abstract: Disclosed in the present disclosure are substances having tyrosine kinase inhibitory activity and a preparation method and use thereof, wherein the substances are the compounds having the structure of general formula (I) or the geometric isomers or pharmaceutical salts thereof. Through evaluation on tyrosine kinase inhibitory activity and related experiments, the present disclosure demonstrates that these compounds have a good tyrosine kinase inhibitory activity, and may inhibit a variety of tumor cells, and thus may be developed into drugs for preventing and treating tumor diseases, especially liver cancer, lung cancer and neuroblastoma.Type: GrantFiled: June 20, 2013Date of Patent: May 9, 2017Assignee: Institute of Radiation Medicine, China Academy of Military Medical Sciences PlaInventors: Xiaoming Yang, Lin Wang, Changyan Li, Yiqun Zhan, Jing Liu, Teng Luo, Haiyan Yan, Shouguo Zhang, Wei Li, Xiaoxue Wen, Tao Peng, Lu Li
-
Publication number: 20160250339Abstract: A pegylated artesunate derivative, a pharmaceutical composition and uses thereof, the pegylated artesunate derivative is represented by the general formula (I): The pegylated artesunate derivative has activity comparable to that of artesunate, increased water solubility and stability, and an extended half-life in vivo.Type: ApplicationFiled: April 12, 2013Publication date: September 1, 2016Applicants: Beijing Kaizheng Biotech Development Co. LTD, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA China, Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA ChinaInventors: Sicheng Li, Qingbin Meng, Junwen Mao, Jinfeng Li, An Xu, Jia Liu, Yuanjun Liang, Qiyan Jia, Jiufeng Yan, Xiaoyang Shen, Hui Liu, Na Xing
-
Publication number: 20160151334Abstract: Disclosed in the present disclosure are substances having tyrosine kinase inhibitory activity and a preparation method and use thereof, wherein the substances are the compounds having the structure of general formula (I) or the geometric isomers or pharmaceutical salts thereof. Through evaluation on tyrosine kinase inhibitory activity and related experiments, the present disclosure demonstrates that these compounds have a good tyrosine kinase inhibitory activity, and may inhibit a variety of tumor cells, and thus may be developed into drugs for preventing and treating tumor diseases, especially liver cancer, lung cancer and neuroblastoma.Type: ApplicationFiled: June 20, 2013Publication date: June 2, 2016Applicant: INSTITUTE OF RADIATION MEDICINE, CHINA ACADEMY OF MILITARY MEDICAL SCIENCES PLAInventors: Xiaoming Yang, Lin Wang, Changyan Li, Yiqun Zhan, Jing Liu, Teng Luo, Haiyan Yan, Shouguo Zhang, Wei Li, Xiaoxue Wen, Tao Peng, Lu Li
-
Patent number: 9029520Abstract: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD.Type: GrantFiled: September 20, 2011Date of Patent: May 12, 2015Assignee: Affiliated Hospital of Academy of Military Medical Sciences, PLAInventors: Yongzhi Xi, Yuan Luo
-
Patent number: 8765925Abstract: A method for preparation of Timosaponin BII, which uses Chinese traditional medicine Rhizoma Anemarrhenae or fresh rhizoma or fibrous root of Anemarrhena asphodeloides Bge. as raw material, and comprises isolation of Timosaponin BII by one or more processes selected from solvent extraction, resin adsorption, polyamide chromatography, reversed phase column chromatography, Sephadex LH-20 column chromatography, etc, combining with conventional drying method such as reduced pressure drying, freeze drying, spray drying, and so on. Timosaponin BII obtained by the present method is of over 90% purity, and the method is simple, practicable and suitable for industrial production.Type: GrantFiled: April 21, 2005Date of Patent: July 1, 2014Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Baiping Ma, Hao Chen, Chengqi Xiong, Liping Kang, Jie Zhang
-
Publication number: 20130344101Abstract: The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD.Type: ApplicationFiled: September 20, 2011Publication date: December 26, 2013Applicant: AFFILIATED HOSPITAL OF ACADEMY OF MILITARY MEDICAL SCIENCES, PLAInventors: Yongzhi Xi, Yuan Luo
-
Publication number: 20130157380Abstract: A multiassay immunochromatographic chip comprises: a viscous bottom lining (1), a sample pad (2), a bonding pad (3), an analysis membrane (4) and a water absorption pad (5). The bonding pad (3) fixedly has a plurality of assay binding substances (6) and a control binding substance (7), the assay binding substance (6) is formed by joining a tracer (8) and a liquid-phase detection probe (9), the control binding substance (7) is formed by joining the tracer (8) and a liquid-phase control probe (11); the analysis membrane (4) is provided with a detection matrix unit (12), each detection matrix unit comprises a detection zone (13) and a control zone (14), wherein the detection zone (13) consists of a plurality of solid phase detection probes (15) and the control zone (14) consists of a solid phase control probe (16). Organic integration of immunochromatographic reaction modes and chip assay matrix settings enables high throughput assay of multiple target substances with one sample load.Type: ApplicationFiled: August 18, 2011Publication date: June 20, 2013Applicant: INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES, PLAInventors: Lei Zhou, Zhaobiao Guo, Ruifu Yang
-
Patent number: 8361795Abstract: Provided are a hepatopoietin PCn (HPPCn) and its homologous proteins, which can promote hepatocyte proliferation in vitro, promote liver regeneration in vivo, inhibit the growth of tumor cells and promote the apoptosis of tumor cells. The hepatopoietin PCn (HPPCn) and its homologous proteins are useful for the treatment of acute and chronic liver injury, or the treatment of liver fibrosis.Type: GrantFiled: December 21, 2007Date of Patent: January 29, 2013Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Zuze Wu, Bingxing Shi, Chunping Cui, Shaojun Du, Danli Wu
-
Publication number: 20120316122Abstract: The present invention relates to a pharmaceutical composition for combating a thrombotic disease and a method for making the same and a use thereof. The pharmaceutical composition mainly comprises timosaponin AIII and timosaponin BII, and optionally pharmaceutically acceptable excipients, characterized in that the amount of timosaponin AIII is greater than or equal to the amount of timosaponin BII. The present invention further relates to a use of timosaponin AIII and timosaponin BII in manufacturing a medicament or product for the prophylaxis or to treatment of a thrombotic disease. The present pharmaceutical composition can not only bring about effects of prophylaxis or treatment of a thrombotic disease, but also alleviate blood bleeding or bleeding tendency in patients.Type: ApplicationFiled: September 7, 2009Publication date: December 13, 2012Applicant: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES ,PLAInventors: Baiping Ma, Yuwen Cong, Liping Kang, Yue Gao, Dawei Tan, Chengqi Xiong, Yang Zhao
-
Patent number: 8212003Abstract: This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.Type: GrantFiled: September 3, 2003Date of Patent: July 3, 2012Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Bingxing Shi, Zuze Wu, Aiping Yu, Chunna Dong
-
Patent number: 8039513Abstract: The present invention relates to cis-1,2-substituted stilbene derivatives, or their pharmaceutically acceptable salts, glucosides or solvates, a pharmaceutical composition comprising the compound, and use of said compound for preparation of a drug for treatment and/or prevention of diabetes or improvement of diabetic complications.Type: GrantFiled: July 20, 2005Date of Patent: October 18, 2011Assignee: Institute of Radiation Medicine, Academy of Military Medical Sciences, PLAInventors: Zhiyun Kang, Zuze Wu, Zhuangrong Sun, Zhongxiong Tang